Roberto Cabrera1,2, Laia Fernández-Barat1,2, Nil Vázquez1,2, Victoria Alcaraz-Serrano1,2, Leticia Bueno-Freire1,2, Rosanel Amaro1,2, Rubén López-Aladid1,2, Patricia Oscanoa1,2, Laura Muñoz3, Jordi Vila3, Antoni Torres1,2. 1. Hospital Clínic, Cellex Laboratory, CIBERES (Center for net Biomedical Research Respiratory diseases, 06/06/0028) - Institut d'Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS), School of Medicine, University of Barcelona, Spain. 2. Respiratory Intensive Care Unit, Pneumology Department, Hospital Clínic, Barcelona, Spain. 3. Barcelona Global Health Institute, Department of Clinical Microbiology, Hospital Clínic, University of Barcelona, Barcelona, Spain.
Abstract
BACKGROUND: Non-cystic fibrosis bronchiectasis (BE) is a chronic structural lung condition that facilitates chronic colonization by different microorganisms and courses with recurrent respiratory infections and frequent exacerbations. One of the main pathogens involved in BE is Pseudomonas aeruginosa. OBJECTIVES: To determine the molecular mechanisms of resistance and the molecular epidemiology of P. aeruginosa strains isolated from patients with BE. METHODS: A total of 43 strains of P. aeruginosa were isolated from the sputum of BE patients. Susceptibility to the following antimicrobials was analysed: ciprofloxacin, meropenem, imipenem, amikacin, tobramycin, aztreonam, piperacillin/tazobactam, ceftazidime, ceftazidime/avibactam, ceftolozane/tazobactam, cefepime and colistin. The resistance mechanisms present in each strain were assessed by PCR, sequencing and quantitative RT-PCR. Molecular epidemiology was determined by MLST. Phylogenetic analysis was carried out using the eBURST algorithm. RESULTS: High levels of resistance to ciprofloxacin (44.19%) were found. Mutations in the gyrA, gyrB, parC and parE genes were detected in ciprofloxacin-resistant P. aeruginosa strains. The number of mutated QRDR genes was related to increased MIC. Different β-lactamases were detected: blaOXA50, blaGES-2, blaIMI-2 and blaGIM-1. The aac(3)-Ia, aac(3)-Ic, aac(6″)-Ib and ant(2″)-Ia genes were associated with aminoglycoside-resistant strains. The gene expression analysis showed overproduction of the MexAB-OprM efflux system (46.5%) over the other efflux system. The most frequently detected clones were ST619, ST676, ST532 and ST109. CONCLUSIONS: Resistance to first-line antimicrobials recommended in BE guidelines could threaten the treatment of BE and the eradication of P. aeruginosa, contributing to chronic infection.
BACKGROUND: Non-cystic fibrosis bronchiectasis (BE) is a chronic structural lung condition that facilitates chronic colonization by different microorganisms and courses with recurrent respiratory infections and frequent exacerbations. One of the main pathogens involved in BE is Pseudomonas aeruginosa. OBJECTIVES: To determine the molecular mechanisms of resistance and the molecular epidemiology of P. aeruginosa strains isolated from patients with BE. METHODS: A total of 43 strains of P. aeruginosa were isolated from the sputum of BE patients. Susceptibility to the following antimicrobials was analysed: ciprofloxacin, meropenem, imipenem, amikacin, tobramycin, aztreonam, piperacillin/tazobactam, ceftazidime, ceftazidime/avibactam, ceftolozane/tazobactam, cefepime and colistin. The resistance mechanisms present in each strain were assessed by PCR, sequencing and quantitative RT-PCR. Molecular epidemiology was determined by MLST. Phylogenetic analysis was carried out using the eBURST algorithm. RESULTS: High levels of resistance to ciprofloxacin (44.19%) were found. Mutations in the gyrA, gyrB, parC and parE genes were detected in ciprofloxacin-resistant P. aeruginosa strains. The number of mutated QRDR genes was related to increased MIC. Different β-lactamases were detected: blaOXA50, blaGES-2, blaIMI-2 and blaGIM-1. The aac(3)-Ia, aac(3)-Ic, aac(6″)-Ib and ant(2″)-Ia genes were associated with aminoglycoside-resistant strains. The gene expression analysis showed overproduction of the MexAB-OprM efflux system (46.5%) over the other efflux system. The most frequently detected clones were ST619, ST676, ST532 and ST109. CONCLUSIONS: Resistance to first-line antimicrobials recommended in BE guidelines could threaten the treatment of BE and the eradication of P. aeruginosa, contributing to chronic infection.
Authors: María García-Castillo; Rosa Del Campo; María Isabel Morosini; Elena Riera; Gabriel Cabot; Rob Willems; Rosa van Mansfeld; Antonio Oliver; Rafael Cantón Journal: J Clin Microbiol Date: 2011-06-22 Impact factor: 5.948
Authors: Ester Del Barrio-Tofiño; Laura Zamorano; Sara Cortes-Lara; Carla López-Causapé; Irina Sánchez-Diener; Gabriel Cabot; Germán Bou; Luis Martínez-Martínez; Antonio Oliver Journal: J Antimicrob Chemother Date: 2019-07-01 Impact factor: 5.790
Authors: Maria Tomás; Michel Doumith; Marina Warner; Jane F Turton; Alejandro Beceiro; German Bou; David M Livermore; Neil Woodford Journal: Antimicrob Agents Chemother Date: 2010-03-01 Impact factor: 5.191
Authors: Rossitza Vatcheva-Dobrevska; Xavier Mulet; Ivan Ivanov; Laura Zamorano; Elina Dobreva; Tzvetan Velinov; Todor Kantardjiev; Antonio Oliver Journal: Microb Drug Resist Date: 2013-04-21 Impact factor: 3.431
Authors: Carlos Juan; Laura Zamorano; Ana Mena; Sebastián Albertí; Jose Luis Pérez; Antonio Oliver Journal: J Antimicrob Chemother Date: 2010-01-12 Impact factor: 5.790
Authors: Mar Solé; Anna Fàbrega; Nazaret Cobos-Trigueros; Laura Zamorano; Mario Ferrer-Navarro; Clara Ballesté-Delpierre; Anna Reustle; Pedro Castro; José Maria Nicolás; Antonio Oliver; José Antonio Martínez; Jordi Vila Journal: J Antimicrob Chemother Date: 2015-08-09 Impact factor: 5.790
Authors: João A Carriço; Maxime Crochemore; Alexandre P Francisco; Solon P Pissis; Bruno Ribeiro-Gonçalves; Cátia Vaz Journal: Algorithms Mol Biol Date: 2018-02-15 Impact factor: 1.405
Authors: Laia Fernández-Barat; Victoria Alcaraz-Serrano; Rosanel Amaro; Antoni Torres Journal: Semin Respir Crit Care Med Date: 2021-07-14 Impact factor: 3.119
Authors: J Mensa; J Barberán; A Soriano; P Llinares; F Marco; R Cantón; G Bou; J González Del Castillo; E Maseda; J R Azanza; J Pasquau; C García-Vidal; J M Reguera; D Sousa; J Gómez; M Montejo; M Borges; A Torres; F Alvarez-Lerma; M Salavert; R Zaragoza; A Oliver Journal: Rev Esp Quimioter Date: 2018-02-23 Impact factor: 1.553